BRCA2 and breast carcinoma: The multivariate odds ratio for contralateral breast cancer associated with tamoxifen use was 0.50 for carriers of BRCA1 mutations (95% CI, 0.30–0.85) and 0.42 for carriers of BRCA2 mutations (95% CI, 0.17–1.02).